Cellectis (CLLS) Liabilities from Discontinued Operations (2022 - 2023)
Cellectis (CLLS) recorded quarterly Liabilities from Discontinued Operations of 17328000.0 in Q1 2023, up 16.58% quarter-over-quarter from 14864000.0 in Q4 2022.
Cellectis (CLLS) Liabilities from Discontinued Operations (2022 - 2023) Analysis & Trends
Cellectis' Liabilities from Discontinued Operations history runs 2 years deep, the most recent figure standing at 17328000.0 for Q1 2023.
- In Q1 2023, Liabilities from Discontinued Operations changed N/A year-over-year to 17328000.0; the TTM figure through Mar 2023 stood at 17328000.0 (changed N/A YoY), while the FY2022 annual figure was 14864000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations was 17328000.0 for Q1 2023 at Cellectis, up from 14864000.0 in the prior quarter.
- In the past five years, Liabilities from Discontinued Operations ranged from a high of 17328000.0 in Q1 2023 to a low of 14864000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Cellectis | 17.40 Bn | 17.21 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 17.33 Mn |
| Mar 31, 2023 | 17.33 Mn |
| Dec 31, 2022 | 14.86 Mn |
| Dec 31, 2022 | 14.86 Mn |